Paper: A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2) -

Oral and Poster Abstracts 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III Clinical Trials, Adults, Non-Biological, Clinical Research, Diseases, Therapies, Myeloid Malignancies, Study Population Nicola Vianelli, MD1*, Giulia Benevolo, MD2*, Alessandro Vannucchi, MD3, Claire N. Harrison, DM4, Michael Loschi, MD, PhD5*,...

123456

DocWire Editors

Fedratinib vs. Best Available Therapy in Myelofibrosis Patients Treated Previous with Ruxolitinib

Read the full article here

See more from DocWire Editors